Altered Metabolomic Profile in Patients with Peripheral Artery Disease
by
Ahmed Ismaeel 1, Marco E. Franco 2, Ramon Lavado 2
, Evlampia Papoutsi 1, George P. Casale 3, Matthew Fuglestad 3, Constance J. Mietus 3, Gleb R. Haynatzki 4, Robert S. Smith 5, William T. Bohannon 5, Ian Sawicki 5, Iraklis I. Pipinos 3 and Panagiotis Koutakis 1,*
Ahmed Ismaeel 1, Marco E. Franco 2, Ramon Lavado 2, Evlampia Papoutsi 1, George P. Casale 3, Matthew Fuglestad 3, Constance J. Mietus 3, Gleb R. Haynatzki 4, Robert S. Smith 5, William T. Bohannon 5, Ian Sawicki 5, Iraklis I. Pipinos 3 and Panagiotis Koutakis 1,*
1
Department of Nutrition, Food and Exercise Sciences, Florida State University, Tallahassee, FL 32306, USA
2
Department of Environmental Science, Baylor University, Waco, TX 76798, USA
3
Department of Surgery, University of Nebraska at Medical Center, Omaha, NE 68198, USA
4
Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE 68198, USA
5
Department of Surgery, Baylor Scott and White Hospital, Temple, TX 76508, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(9), 1463; https://doi.org/10.3390/jcm8091463
Received: 24 August 2019 / Revised: 11 September 2019 / Accepted: 12 September 2019 / Published: 14 September 2019
(This article belongs to the Special Issue Cardiovascular Disease: From Molecular Mechanisms to Clinical Therapies)
Peripheral artery disease (PAD) is a common atherosclerotic disease characterized by narrowed or blocked arteries in the lower extremities. Circulating serum biomarkers can provide significant insight regarding the disease progression. Here, we explore the metabolomics signatures associated with different stages of PAD and investigate potential mechanisms of the disease. We compared the serum metabolites of a cohort of 26 PAD patients presenting with claudication and 26 PAD patients presenting with critical limb ischemia (CLI) to those of 26 non-PAD controls. A difference between the metabolite profiles of PAD patients from non-PAD controls was observed for several amino acids, acylcarnitines, ceramides, and cholesteryl esters. Furthermore, our data demonstrate that patients with CLI possess an altered metabolomic signature different from that of both claudicants and non-PAD controls. These findings provide new insight into the pathophysiology of PAD and may help develop future diagnostic procedures and therapies for PAD patients.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Ismaeel, A.; Franco, M.E.; Lavado, R.; Papoutsi, E.; Casale, G.P.; Fuglestad, M.; Mietus, C.J.; Haynatzki, G.R.; Smith, R.S.; Bohannon, W.T.; Sawicki, I.; Pipinos, I.I.; Koutakis, P. Altered Metabolomic Profile in Patients with Peripheral Artery Disease. J. Clin. Med. 2019, 8, 1463.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
- Supplementary File 1:
PDF-Document (PDF, 105 KB)
